Seattle Genetics, an American-based oncology company, is back in the news again. This particular company is looking to step its game-up by becoming one of a handful of successful pharmaceutical companies. The captain of the ship over here is Dr. Clay Siegall, and he is the man of the hour thanks to his brilliance in cancer research. Dr. Siegall has been involved in cancer research for more than 30 years, and he has worked with various industry-related companies such as Bristol Myers Squibb, the National Institute of Health and the National Cancer Society. His resume is that of legends and then some, which is why he is so well-respected.
Dr. Clay Siegall has always had a love for technology and how it applies to medicine. When he was 19 years old, his father became ill with cancer. During that particular time, cancer treatments were very harsh. In some cases, cancer patients would have to endure radical surgeries as well as endure amputation. “There had to be a better way to fight this disease,” said Siegall. Unfortunately, his father passed-away about five years later, but his father’s death put the ball into motion. As of today, Dr. Siegall is the CEO and founder of Seattle Genetics. This biotech-oncology company specializes in the development and the commercialization of antibody-based therapies. The company’s premier drug, ADCETRIS, has become a game changer thanks to its ability to affectively eradicate cancer cells in the body. In just five short years, Seattle Genetics’ stock has risen dramatically.
Dr. Siegall was able to enter ADCETRIS into multiple strategic deals with other pharmaceutical companies. This deal would allow ADCETRIS to be used on a global scale. As of now, this top-of-the-line drug is being used in 70 different countries and that speaks volumes.